166 related articles for article (PubMed ID: 34881446)
1. Nivolumab-induced localized genital bullous pemphigoid in a 60-year-old male.
Alvarado SM; Weston G; Murphy MJ; Stewart CL
J Cutan Pathol; 2022 May; 49(5):468-471. PubMed ID: 34881446
[TBL] [Abstract][Full Text] [Related]
2. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature.
Fisler RE; Saeb M; Liang MG; Howard RM; McKee PH
Am J Dermatopathol; 2003 Jun; 25(3):183-9. PubMed ID: 12775979
[TBL] [Abstract][Full Text] [Related]
3. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.
Khazaeli M; Grover R; Pei S
J Cutan Pathol; 2023 Jun; 50(6):520-523. PubMed ID: 36601731
[TBL] [Abstract][Full Text] [Related]
4. Symmetrical Skin Lesions on the Gluteal Region in a Patient with Anti-Laminin-332 Mucous Membrane Pemphigoid.
Maki N; Demitsu T; Nagato H; Okada O; Yoneda K; Hashimoto T; Hasunuma N; Osada I; Manabe M
Acta Dermatovenerol Croat; 2021 Jul; 29(2):105-107. PubMed ID: 34477077
[TBL] [Abstract][Full Text] [Related]
5. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia.
Maki N; Demitsu T; Umemoto N; Nagashima K; Nakamura T; Kakurai M; Nakamura S; Yamada T; Ishii N; Hashimoto T
J Dermatol; 2016 May; 43(5):571-4. PubMed ID: 26507447
[TBL] [Abstract][Full Text] [Related]
6. Linear IgA dermatosis with IgA and IgG autoantibodies to the 180 kDa bullous pemphigoid antigen (BP180): evidence for a distinct subtype.
Metz BJ; Ruggeri SY; Hsu S; Reed JA; Ghohestani AS; Uitto J; Ghohestani RF
Int J Dermatol; 2004 Jun; 43(6):443-6. PubMed ID: 15186228
[TBL] [Abstract][Full Text] [Related]
7. Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid.
Liu M; Yuan M; Sun W; Li Z; Zhou X; Wang C
Invest New Drugs; 2023 Dec; 41(6):802-807. PubMed ID: 37773473
[TBL] [Abstract][Full Text] [Related]
8. Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum.
Yu-Yang S; Chu-Sung Hu S; Yiao-Lin S
Acta Dermatovenerol Croat; 2017 Oct; 25(3):255-256. PubMed ID: 29252183
[TBL] [Abstract][Full Text] [Related]
9. A Case of Possible Concurrence of Dermatitis Herpetiformis and Linear Immunoglobulin A / Immunoglobulin G Bullous Dermatosis.
Minakawa S; Matsuzaki Y; Hashimoto T; Ishii N; Nishie W; Sawamura D
Acta Dermatovenerol Croat; 2021 Jul; 29(2):116-117. PubMed ID: 34477081
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid.
Zheng M; Ujiie H; Iwata H; Muramatsu K; Yoshimoto N; Ito T; Ujiie I; Shimizu S; Sato-Matsumura KC; Shimizu H
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):595-600. PubMed ID: 30394605
[TBL] [Abstract][Full Text] [Related]
11. A child with antibodies targeting both linear IgA bullous dermatosis and bullous pemphigoid antigens.
Darling TN; Cardenas AA; Beard JS; Sau P; Yee CL; Zone JJ; Yancey KB
Arch Dermatol; 1995 Dec; 131(12):1438-42. PubMed ID: 7492135
[TBL] [Abstract][Full Text] [Related]
12. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.
Amber KT; Murrell DF; Schmidt E; Joly P; Borradori L
Clin Rev Allergy Immunol; 2018 Feb; 54(1):26-51. PubMed ID: 28779299
[TBL] [Abstract][Full Text] [Related]
14. [Subepidermal bullous autoimmune dermatosis with linear deposition of IgA amd IgG].
Kersting E; Goebeler M; Hamm H; Rose C; Zillikens D; Bröcker EB
Hautarzt; 2000 May; 51(5):340-4. PubMed ID: 10875072
[TBL] [Abstract][Full Text] [Related]
15. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.
Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T
Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764
[TBL] [Abstract][Full Text] [Related]
16. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.
Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P
Front Immunol; 2019; 10():1934. PubMed ID: 31474998
[TBL] [Abstract][Full Text] [Related]
18. Bullous pemphigoid (BP) patients with selective IgG autoreactivity against BP230: Review of a rare but valuable cohort with impact on the comprehension of the pathogenesis of BP.
Ramcke T; Vicari E; Bolduan V; Enk A; Hadaschik E
J Dermatol Sci; 2022 Feb; 105(2):72-79. PubMed ID: 34930674
[TBL] [Abstract][Full Text] [Related]
19. Atypical Bullous Pemphigoid After Linagliptin Intake.
Dbouk S; Bazzi N; Saad WA; Toribio A; Habre M; Salloum A
Am J Case Rep; 2021 Sep; 22():e932356. PubMed ID: 34584063
[TBL] [Abstract][Full Text] [Related]
20. Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease.
Izumi R; Fujimoto M; Yazawa N; Nakashima H; Asashima N; Watanabe R; Kuwano Y; Kurokawa M; Hashimoto T; Tamaki K
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S94-7. PubMed ID: 17434049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
